stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Return on assets
GeneDx Holdings Corp.'s return on assets over the twelve months to 30 June 2026 was −22.5%, down 18.0 percentage points from fiscal 2025 (−4.46%). Over the past ten years it has ranged from −191.8% (fiscal 2020) to 0.00% (fiscal 2019); the current reading is higher than 86% of that period. That is below the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −4.46% | 8.02 |
| FY2024 | −12.5% | 26.16 |
| FY2023 | −38.6% | 66.42 |
| FY2022 | −105.1% | (44.15) |
| FY2021 | −60.9% | 130.90 |
| FY2020 | −191.8% | (191.81) |
| FY2019 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CDNA CareDx, Inc. compare | 24.0% |
| VCYT Veracyte, Inc. compare | 8.63% |
| FRNM Freenome, Inc compare | −0.86% |
| NEO NeoGenomics, Inc. compare | −2.35% |
| CSTL Castle Biosciences, Inc. compare | −4.03% |
| OPK OPKO Health, Inc. compare | −7.64% |
| ADPT Adaptive Biotechnologies Corporation compare | −12.0% |
| WGS GeneDx Holdings Corp. | −22.5% |
| PSNL Personalis, Inc. compare | −44.7% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement